NRX Pharmaceuticals IncNASDAQ:NRXPNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE1.1900
- TODAY'S CHANGE (%)0.0300 (2.5862%)
- Bid / Lots1.1500/ 29
- Ask / Lots1.2500/ 50
- Open / Previous Close1.1600 / 1.1600
- Day Range
- 52 Week Range
- Volume102,989
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NRXP |
|---|---|---|
| 09:32 ET | 2458 | 1.16 |
| 09:33 ET | 5508 | 1.16 |
| 09:42 ET | 2727 | 1.15 |
| 09:46 ET | 1508 | 1.1299 |
| 09:48 ET | 7646 | 1.1499 |
| 09:50 ET | 700 | 1.1401 |
| 09:53 ET | 9177 | 1.1404 |
| 10:04 ET | 4462 | 1.16 |
| 10:09 ET | 136 | 1.16 |
| 10:11 ET | 10573 | 1.18 |
| 10:20 ET | 923 | 1.1665 |
| 10:26 ET | 2300 | 1.16 |
| 10:31 ET | 1000 | 1.153 |
| 10:36 ET | 537 | 1.1539 |
| 10:56 ET | 2119 | 1.15 |
| 10:58 ET | 700 | 1.1593 |
| 11:07 ET | 1300 | 1.1597 |
| 11:09 ET | 250 | 1.159 |
| 11:12 ET | 500 | 1.155 |
| 11:14 ET | 1186 | 1.16 |
| 11:20 ET | 2327 | 1.16 |
| 11:21 ET | 1000 | 1.1514 |
| 11:38 ET | 711 | 1.16 |
| 11:43 ET | 1000 | 1.16 |
| 11:54 ET | 3289 | 1.16 |
| 11:57 ET | 2000 | 1.1601 |
| 12:01 ET | 100 | 1.1662 |
| 12:14 ET | 2593 | 1.17 |
| 12:24 ET | 1405 | 1.1671 |
| 12:30 ET | 100 | 1.17 |
| 12:32 ET | 200 | 1.17 |
| 12:51 ET | 250 | 1.1694 |
| 12:57 ET | 100 | 1.165 |
| 01:00 ET | 150 | 1.167 |
| 01:09 ET | 1309 | 1.1601 |
| 01:18 ET | 200 | 1.175 |
| 01:22 ET | 1175 | 1.17 |
| 01:40 ET | 427 | 1.1668 |
| 01:42 ET | 100 | 1.17 |
| 01:44 ET | 500 | 1.17 |
| 02:32 ET | 850 | 1.17 |
| 02:34 ET | 1300 | 1.1665 |
| 02:41 ET | 100 | 1.165 |
| 02:45 ET | 2100 | 1.165 |
| 03:19 ET | 890 | 1.195 |
| 03:24 ET | 100 | 1.195 |
| 03:26 ET | 427 | 1.1998 |
| 03:28 ET | 170 | 1.1901 |
| 03:30 ET | 100 | 1.1988 |
| 03:32 ET | 200 | 1.1937 |
| 03:33 ET | 1000 | 1.1901 |
| 03:37 ET | 120 | 1.1987 |
| 03:39 ET | 5214 | 1.195 |
| 03:42 ET | 750 | 1.2 |
| 03:46 ET | 300 | 1.199 |
| 03:48 ET | 1150 | 1.1991 |
| 03:51 ET | 200 | 1.19 |
| 04:00 ET | 637 | 1.19 |
Nov 15, 2024
DJ NRX Pharmaceuticals Is Maintained at Buy by D. Boral Capital, from 5:09PM ET on Friday Nov 15, 2024 by Dow Jones
5:09PM ET on Friday Nov 15, 2024 by Dow Jones
Nov 14, 2024
NRx Pharmaceuticals (NASDAQ:NRXP) Reports Third Quarter and Year to Date 2024 Financial Results and Provides Business Update, from 4:05PM ET on Thursday Nov 14, 2024 by Dow Jones
4:05PM ET on Thursday Nov 14, 2024 by Dow JonesPress Release: NRx Pharmaceuticals (NASDAQ:NRXP) Reports Third Quarter and Year to Date 2024 Financial Results and Provides Business Update, from 4:05PM ET on Thursday Nov 14, 2024 by Dow Jones
4:05PM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 13, 2024
Nov 7, 2024
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Third Quarter and Year to Date 2024 Financial Results on November 14, 2024, from 4:06PM ET on Thursday Nov 07, 2024 by Dow Jones
4:06PM ET on Thursday Nov 07, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
NRX Pharmaceuticals Inc | 12.8M | -0.7x | --- |
PharmaCyte Biotech Inc | 12.6M | 3.2x | --- |
Protext Mobility Inc | 12.3M | 0.0x | --- |
Cingulate Inc | 13.5M | -0.1x | --- |
Inhibitor Therapeutics Inc | 13.8M | -4.6x | --- |
Oncotelic Therapeutics Inc | 12.1M | -9.7x | --- |
Company Information
NRX Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and post-traumatic stress disorder (PTSD). The Company has two lead compounds, NRX-100, a proprietary presentation of ketamine and NRX-101, a fixed-dose combination of D-cycloserine (DCS) and lurasidone. The Company is developing NRX-101, a Food and Drug Administration (FDA)-designated investigational therapy for suicidal treatment-resistant bipolar depression and chronic pain. NRX-101 is a combined NMDA/5-HT2A-targeted medicine designed to address both depression and suicidal ideation, consisting of an oral, fixed dose combination of DCS and lurasidone. Its NRX-100 is racemic ketamine, which is a generic anesthetic. The Company is also engaged in the development of its new product, NRX-102.
Contact Information
- Headquarters
- 1201 ORANGE STREET, SUITE 600WILMINGTON, DE, United States 19801
- Phone
- 484-254-6134
- Fax
- 302-575-1642
Executives
- Chairman of the Board, Interim Chief Executive Officer, Chief Scientific Officer
- Jonathan Javitt
- Interim Chief Financial Officer
- Richard Narido
- CMC and Technical Operations Advisor
- Riccardo Panicucci
- Independent Director
- Patrick Flynn
- Independent Director
- Sharon Glied
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $12.8M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 10.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.26 |
EPS | $-1.69 |
Book Value | $-0.14 |
P/E Ratio | -0.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
